cropped-gtc_logo_grey_circle_2022

ASH22 Posters

ASH22 Posters

GTC presented abstracts at ASH 2022

GTC’s posters from 2022 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions.

Read more Articles and News from GTC

CorePath Laboratories Internalizes Genomic Testing Cooperative’s State-Of-The-Art Next-Generation Sequencing (NGS) Testing for Solid Tumors and Hematologic Neoplasms 
Press Releases

CorePath Laboratories Internalizes Genomic Testing Cooperative’s State-Of-The-Art Next-Generation Sequencing (NGS) Testing for Solid Tumors and Hematologic Neoplasms 

CorePath Laboratories is partnering with Genomic Testing Cooperative (GTC) to enhance its next-generation sequencing (NGS) capabilities for cancer diagnostics. This collaboration combines targeted DNA and RNA profiling with other pathology testing methods, providing comprehensive evaluations of patient samples. Additionally, liquid biopsy capabilities offer a non-invasive way to monitor therapy and detect relapse.

Read More »
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation
Publications

Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation

Acute graft-versus-host disease (aGvHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), occurring to some degree in over 50% of patients and being a direct cause of death in about 20% of patients. This complication occurs even despite a better understanding of donor selection and GvHD prophylaxis regimens. aGvHD is a complex event in which multiple contributing factors are involved. We performed RNA transcriptome analysis of 1408 genes in bone marrow samples obtained before and after transplantation using machine learning to predict the risk of aGvHD and post-transplant survival for a cohort of patients undergoing HSCT. Differential gene expression identified several signaling pathways in the bone marrow microenvironment that may be major regulators of the complex biology of GvHD, and identified targets of intervention to ameliorate the risk of aGvHD and improve patient survival.

Read More »
Combining cell-free RNA with cell-free DNA in liquid biopsy forhematologic and solid tumors
Publications

Combining cell-free RNA with cell-free DNA in liquid biopsy forhematologic and solid tumors

Introducing a novel liquid biopsy approach combining cfRNA and cfDNA sequencing. Our findings demonstrate superior mutation detection with cfRNA, while cfDNA excels in identifying chromosomal aberrations. Elevated cfRNA biomarkers correlate with tumor types, aiding diagnosis. Machine learning predicts cancer types accurately. Host immune response analysis through cfRNA ratios reveals distinct patterns in cancer patients. This integrated approach holds promise for predicting genomic abnormalities and cancer diagnosis

Read More »
San Antonio Breast Cancer Review 2023
Events

San Antonio Breast Cancer Review 2023

John Theurer Cancer presents the 2023 San Antonio Breast Cancer Review: This program, based on data presented at the San Antonio Breast Cancer Symposium 2023, is designed to provide a review of state of the art information on experimental biology, etiology, prevention, diagnosis & therapy of breast cancer/premalignant breast disease to an audience of academic and private physicians and researchers involved in medical, surgical, GYN and radiation therapy, as well as other appropriate health care professionals

Read More »

YOU MAY ALSO ENJOY THESE ARTICLES:

Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends